Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Nanologica AB ( (SE:NICA) ) just unveiled an announcement.
Nanologica AB has secured a SEK 1.5 million order for a new non-silica-based purification media from an Asian customer, marking an early success in their development program aimed at broadening their chromatography media portfolio. The order, expected to be delivered in the first quarter of next year, could potentially enhance the company’s revenue stream in the long term, reflecting positively on its strategic market positioning and operational growth.
The most recent analyst rating on (SE:NICA) stock is a Sell with a SEK1.00 price target. To see the full list of analyst forecasts on Nanologica AB stock, see the SE:NICA Stock Forecast page.
More about Nanologica AB
Nanologica AB is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. The company specializes in purification products for peptide drugs, such as insulin and GLP-1 analogues, aiming to increase productivity and reduce costs for pharmaceutical manufacturers. Operating in a growing global niche market driven by the demand for diabetes and obesity treatments, Nanologica is committed to making cost-effective drugs more accessible worldwide.
Average Trading Volume: 120,729
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK88.36M
For an in-depth examination of NICA stock, go to TipRanks’ Overview page.